EdgarLookup

Clearside Biomedical, Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Clearside Biomedical, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $201.0K Nov 14, 2025
Q2 2025 Jun 30, 2025 $492.0K Aug 8, 2025
Q1 2025 Mar 31, 2025 $2.33M May 15, 2025
Q3 2025 Sep 30, 2024 $1.04M Nov 14, 2025
Q2 2025 Jun 30, 2024 $90.0K Aug 8, 2025
Q1 2025 Mar 31, 2024 $230.0K May 15, 2025
Q3 2024 Sep 30, 2023 $859.0K Nov 12, 2024
Q2 2024 Jun 30, 2023 $1.02M Aug 12, 2024
Q1 2024 Mar 31, 2023 $4.0K May 10, 2024
Q3 2023 Sep 30, 2022 $266.0K Nov 13, 2023
Q2 2023 Jun 30, 2022 $384.0K Aug 14, 2023
Q1 2023 Mar 31, 2022 $347.0K May 12, 2023
Q3 2022 Sep 30, 2021 $3.07M Nov 9, 2022
Q2 2022 Jun 30, 2021 $780.0K Aug 12, 2022
Q1 2022 Mar 31, 2021 $34.0K May 12, 2022
Q3 2021 Sep 30, 2020 $3.43M Nov 10, 2021
Q2 2021 Jun 30, 2020 $354.0K Aug 10, 2021
Q1 2021 Mar 31, 2020 $4.10M May 17, 2021
Q3 2020 Sep 30, 2019 $141.0K Nov 10, 2020
Q2 2020 Jun 30, 2019 $45.0K Aug 10, 2020

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($5.97M) Nov 14, 2025
Q3 2025 Jun 30, 2025 ($4.50M) Nov 14, 2025
Q2 2025 Jun 30, 2025 ($4.50M) Aug 8, 2025
Q2 2025 Mar 31, 2025 ($8.22M) Aug 8, 2025
Q3 2025 Mar 31, 2025 ($8.22M) Nov 14, 2025
Q1 2025 Mar 31, 2025 ($8.22M) May 15, 2025
Q3 2025 Sep 30, 2024 ($7.69M) Nov 14, 2025
Q2 2025 Jun 30, 2024 ($7.59M) Aug 8, 2025
Q3 2025 Jun 30, 2024 ($7.60M) Nov 14, 2025
Q2 2025 Mar 31, 2024 ($11.76M) Aug 8, 2025
Q3 2025 Mar 31, 2024 ($11.76M) Nov 14, 2025
Q1 2025 Mar 31, 2024 ($11.76M) May 15, 2025
Q3 2024 Sep 30, 2023 ($9.27M) Nov 12, 2024
Q2 2024 Jun 30, 2023 ($9.11M) Aug 12, 2024
Q3 2024 Jun 30, 2023 ($9.11M) Nov 12, 2024
Q2 2024 Mar 31, 2023 ($9.28M) Aug 12, 2024
Q3 2024 Mar 31, 2023 ($9.28M) Nov 12, 2024
Q1 2024 Mar 31, 2023 ($9.28M) May 10, 2024
Q3 2023 Sep 30, 2022 ($7.83M) Nov 13, 2023
Q3 2023 Jun 30, 2022 ($7.81M) Nov 13, 2023

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($7.04M) Nov 14, 2025
Q2 2025 Jun 30, 2025 ($3.57M) Aug 8, 2025
Q1 2025 Mar 31, 2025 ($5.21M) May 15, 2025
Q3 2025 Sep 30, 2024 ($5.93M) Nov 14, 2025
Q2 2025 Jun 30, 2024 ($7.59M) Aug 8, 2025
Q1 2025 Mar 31, 2024 ($8.21M) May 15, 2025
Q3 2024 Sep 30, 2023 ($7.05M) Nov 12, 2024
Q2 2024 Jun 30, 2023 ($7.27M) Aug 12, 2024
Q1 2024 Mar 31, 2023 ($7.61M) May 10, 2024
Q3 2023 Sep 30, 2022 ($6.72M) Nov 13, 2023
Q2 2023 Jun 30, 2022 ($7.84M) Aug 14, 2023
Q1 2023 Mar 31, 2022 ($7.65M) May 12, 2023
Q3 2022 Sep 30, 2021 ($4.89M) Nov 9, 2022
Q2 2022 Jun 30, 2021 ($6.10M) Aug 12, 2022
Q1 2022 Mar 31, 2021 ($8.35M) May 12, 2022
Q3 2021 Sep 30, 2020 ($2.43M) Nov 10, 2021
Q2 2021 Jun 30, 2020 ($5.56M) Aug 10, 2021
Q1 2021 Mar 31, 2020 ($2.84M) May 17, 2021
Q3 2020 Sep 30, 2019 ($6.37M) Nov 10, 2020
Q2 2020 Jun 30, 2019 ($5.62M) Aug 10, 2020